Author

Saptaparna Mukherjee

The Francis Crick InstituteORCID 0000-0002-8704-481XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Julian DownwardiD· 2 shared Alicia Alonso de la VegaiD· 1 shared An Nhien TruongiD· 1 shared Andrea de CastroiD· 1 shared Ania Mikolajczak· 1 shared Arturo Simoni NievesiD· 1 shared Ashish NoronhaiD· 1 shared Boobash-Raj Selvadurai· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Julian DownwardORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 27, 2025

Leveraging death of drug-sensitive cancer cells to promote immune-mediated bystander killing of subclones of drug-resistant tumor cells

Mona Tomaschko, KangBo Ng, Christopher Moore…·Julian Downward

This study shows that targeting drug-sensitive cancer cells with G12Ci inhibitors and combining it with immune therapies can eliminate drug-resistant subclones through immune-mediated bystander killing.

DOI 10.1101/2025.10.27.684825

mouseexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJun 23, 2025

Sensitizing Immune-Refractory Ovarian Tumors via p53 Mutation-Tailored Immunotherapy

Rishita Chatterjee, Arturo Simoni Nieves, An Nhien Truong…·Yosef Yarden

This study identifies a p53 mutation-specific immunotherapy strategy for ovarian cancer by targeting AREG and PD-L1, showing efficacy in mouse models and patient-derived organoids.

1 citation

mousehuman

𝕏 PostBluesky